February 26th, 2016
Posted by Caroline Popper, M.D., M.P.H.
The recent partnership between Diversigen and Baylor Miraca Genetics highlights the importance of both human genetics and the microbiome in drug development and ultimately in clinical decision making.
We are in the early days of understanding the scope of the impact of the microbiome but we already know of powerful associations in diseases as diverse as inflammatory bowel disease, diabetes and cancer.
We are excited about this partnership as it leverages real technical and interpretive expertise across across a broad array of genomes relevant to human health.